CLOs on the Move

Synthekine

www.synthekine.com

 
Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Selexys Pharmaceuticals

Selexys Pharmaceuticals is a Oklahoma City, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calysta

Calysta, Inc., Menlo Park, CA, is a biotechnology company working towards a future where the world`s growing population has guaranteed food security. Calysta`s aim is to make more from less by fermenting natural gas to create new food products, creating sustainable, high value nutritional ingredients that don`t interfere with the human food chain.

Pearson Dental Supply

Pearson Dental Supply is a Sylmar, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AmacaThera

AmacaThera is a Toronto-based biotechnology company focused on developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications.

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.